No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Kyverna Therapeutics Sets 2025 Strategic Priorities for Growth
Express News | Kyverna Therapeutics Inc - Has Cash Runway Into 2027
Express News | Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
Express News | Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
Press Release: Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth